Trials / Completed
CompletedNCT01714739
A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors
A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 337 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability and preliminary anti-tumor activity of lirilumab (BMS-986015) given in combination with nivolumab (BMS-936558) and to identify dose limiting toxicities (DLTs) and the maximally tolerated dose (MTD) of the combination. In addition, to assess the combinations of lirilumab and nivolumab or lirilumab and nivolumab plus ipilimumab (BMS-734016) in subjects with advanced (metastatic and/or unresectable) refractory solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lirilumab | Specified dose on specified days. |
| DRUG | Nivolumab | Specified dose on specified days. |
| DRUG | Ipilimumab | Specified dose on specified days. |
Timeline
- Start date
- 2012-10-07
- Primary completion
- 2019-12-13
- Completion
- 2019-12-13
- First posted
- 2012-10-26
- Last updated
- 2023-02-02
- Results posted
- 2023-02-02
Locations
30 sites across 6 countries: United States, Canada, France, Italy, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01714739. Inclusion in this directory is not an endorsement.